HOB Biotech Group Corp Ltd (688656) - Total Assets
Based on the latest financial reports, HOB Biotech Group Corp Ltd (688656) holds total assets worth CN¥912.83 Million CNY (≈ $133.58 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can HOB Biotech Group Corp Ltd service its debt to assess how comfortably operating cash covers total debt obligations.
HOB Biotech Group Corp Ltd - Total Assets Trend (2016–2025)
This chart illustrates how HOB Biotech Group Corp Ltd's total assets have evolved over time, based on quarterly financial data. See HOB Biotech Group Corp Ltd (688656) shareholders funds for net asset value and shareholders' equity analysis.
HOB Biotech Group Corp Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
HOB Biotech Group Corp Ltd's total assets of CN¥912.83 Million consist of 25.3% current assets and 74.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 6.8% |
| Accounts Receivable | CN¥57.00 Million | 6.1% |
| Inventory | CN¥107.08 Million | 11.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥11.06 Million | 1.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how HOB Biotech Group Corp Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of HOB Biotech Group Corp Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HOB Biotech Group Corp Ltd's current assets represent 25.3% of total assets in 2025, a decrease from 42.3% in 2016.
- Cash Position: Cash and equivalents constituted 6.8% of total assets in 2025, down from 10.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 11.5% of total assets.
HOB Biotech Group Corp Ltd Competitors by Total Assets
Key competitors of HOB Biotech Group Corp Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351
|
China | CN¥2.00 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Vitrolife AB
ST:VITR
|
Sweden | Skr11.24 Billion |
|
Imricor Medical Systems Inc
AU:IMR
|
Australia | AU$45.79 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
HOB Biotech Group Corp Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.75 | 1.56 | 3.50 |
| Quick Ratio | 1.40 | 0.88 | 2.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥144.91 Million | CN¥94.31 Million | CN¥152.30 Million |
HOB Biotech Group Corp Ltd - Advanced Valuation Insights
This section examines the relationship between HOB Biotech Group Corp Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.96 |
| Latest Market Cap to Assets Ratio | 0.87 |
| Asset Growth Rate (YoY) | -9.8% |
| Total Assets | CN¥931.30 Million |
| Market Capitalization | $808.92 Million USD |
Valuation Analysis
Near Book Valuation: The market values HOB Biotech Group Corp Ltd's assets close to their book value (0.87x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: HOB Biotech Group Corp Ltd's assets decreased by 9.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for HOB Biotech Group Corp Ltd (2016–2025)
The table below shows the annual total assets of HOB Biotech Group Corp Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥931.30 Million ≈ $136.28 Million |
-9.83% |
| 2024-12-31 | CN¥1.03 Billion ≈ $151.13 Million |
+8.80% |
| 2023-12-31 | CN¥949.26 Million ≈ $138.91 Million |
+0.50% |
| 2022-12-31 | CN¥944.56 Million ≈ $138.22 Million |
+9.33% |
| 2021-12-31 | CN¥863.92 Million ≈ $126.42 Million |
+191.46% |
| 2020-12-31 | CN¥296.41 Million ≈ $43.37 Million |
+4.67% |
| 2019-12-31 | CN¥283.18 Million ≈ $41.44 Million |
+25.73% |
| 2018-12-31 | CN¥225.22 Million ≈ $32.96 Million |
+56.16% |
| 2017-12-31 | CN¥144.22 Million ≈ $21.10 Million |
+15.70% |
| 2016-12-31 | CN¥124.65 Million ≈ $18.24 Million |
-- |
About HOB Biotech Group Corp Ltd
HOB Biotech Group Corp.,Ltd. operates as an in vitro diagnostic company in China and internationally. It provides diagnostic tools, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immune assays to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. HOB Biotech Group Corp.,Ltd was founded in 2009 and is ba… Read more